Novel irreversible peptidic inhibitors of transglutaminase 2
Nicholas J. Cundy, Jane Arciszewski, Eric W. J. Gates, Sydney L. Acton, Kyle D. Passley, Ernest Awoonor‐Williams, Elizabeth Boyd, Nancy Xu, Élise Pierson, Catalina Fernandez-Ansieta, Marie R. Albert, Nicole M. R. McNeil, Gautam Adhikary, Richard L. Eckert, Jeffrey W. Keillor
Abstract
ratios nearly ten-fold higher than their parent compound, their pharmacokinetic properties and cellular activity limit their therapeutic potential. However, they do serve as a scaffold for the development of potent research tools.
Topics & Concepts
Tissue transglutaminaseChemistryComputational biologyBiochemistryEnzymeBiologyBlood properties and coagulation